Evaluation of albumin utilization, guideline compliance, and cost in intensive care units: a multicenter point prevalence study
Rattachement africain : tr, us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
BACKGROUND: Intravenous (IV) albumin is widely used in intensive care units (ICUs), yet its use often deviates from evidence-based recommendations, leading to unnecessary costs. This study evaluates the indications for the use of IV albumin in critically ill patients, compliance with the 2024 "Use of Intravenous Albumin" guidelines, and the associated cost burden. METHODS: A prospective, point prevalence-based observational study was conducted across seven hospitals in Türkiye over one week. Data on IV albumin utilization, guideline compliance, patient demographic and clinical characteristics, and associated costs were collected and analyzed. Statistical analyses included the Kruskal-Wallis test for comparisons of albumin utilization and logistic regression to assess factors influencing its use. RESULTS: Among 385 ICU patients monitored, 56 (14.5%) received IV albumin therapy. The median age was 68 years (Interquartile range-IQR: 54.2-77.7), and 67.9% were male. The most common physician-reported indications for initiating albumin therapy were low serum albumin levels (41.1%), fluid shifts or intravascular volume support (21.4%), and sepsis or septic shock (14.3%). The desired clinical target was achieved in 73.2% of cases; however, guideline compliance was 0%. Albumin use differed significantly across ICU types (p = 0.049), with a median consumption of 667 (IQR: 250-1,083) vials per 1,000 patient-days and an estimated cost of $70,617.86. Logistic regression identified total hospital stay (p = 0.028) and Acute Physiology and Chronic Health Evaluation (APACHE) II score (p = 0.040) as significant predictors, while mechanical ventilation (MV) duration showed borderline significance (p = 0.070). The model's classification accuracy was 78.6%. CONCLUSION: This study highlights widespread non-compliance with guidelines for IV albumin use in ICUs, resulting in substantial costs. These findings underscore the need to improve compliance with evidence-based guidelines to optimize albumin utilization and reduce economic burden. Future studies should explore the potential impact of targeted interventions, including pharmacist involvement, on improving prescribing practices. CLINICAL TRIAL NUMBER: Not applicable. TRIAL REGISTRATION: Not applicable.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Evaluation of albumin utilization, guideline compliance, and cost in intensive care units: a multicenter point prevalence study
- Date Crossref
- 06/06/2026
- Éditeur
- Springer Science and Business Media LLC
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Inonu University pays non établi dans la noticeUniversité ou école supérieure
-
Istanbul University-Cerrahpaşa pays non établi dans la noticeUniversité ou école supérieure
-
Istanbul University pays non établi dans la noticeUniversité ou école supérieure
-
Afyonkarahisar Sağlık Bilimleri Üniversitesi pays non établi dans la noticeUniversité ou école supérieure
-
Afyon Kocatepe University pays non établi dans la noticeUniversité ou école supérieure
-
Education Training And Research pays non établi dans la noticeOrganisation à but non lucratif
-
Gaziosmanpaşa Taksim Eğitim ve Araştırma Hastanesi pays non établi dans la noticeÉtablissement de santé
-
İstanbul Başakşehir Çam ve Sakura Şehir Hastanesi pays non établi dans la noticeÉtablissement de santé
-
Dr Lütfi Kırdar Kartal Eğitim ve Araştırma Hastanesi pays non établi dans la noticeÉtablissement de santé
-
Bezmiâlem Vakıf Üniversitesi pays non établi dans la noticeUniversité ou école supérieure
-
Faculty of Pharmacy Department of Clinical Pharmacy pays non établi dans la noticeUniversité ou école supérieure
-
Department of Clinical Pharmacy pays non établi dans la noticeÉtablissement de santé
Inonu University, Istanbul University-Cerrahpaşa et Istanbul University, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.